Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11918894 | 1.00 | ADRA2C (0.41) | ADRA2CKMT2AMEN1PABPC1ALDH1A1 | |
| SCHEMBL361227 | 0.76 | ADRA2C (0.39) | ADRA2CKMT2AMEN1PABPC1ALDH1A1 | |
| SCHEMBL8826943 | 0.76 | ADRA2C (0.42) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL13391600 | 0.76 | ADRA2C (0.42) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL5711438 | 0.75 | ADRA2C (0.35) | ADRA2CKMT2AMEN1PABPC1 | |
| SCHEMBL23941234 | 0.74 | ADRA2C (0.38) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL361225 | 0.74 | ALDH1A1 (0.36) | ADRA2CKMT2AMEN1PABPC1ALDH1A1 | |
| SCHEMBL631042 | 0.74 | ALDH1A1 (0.32) | ADRA2CKMT2AMEN1PABPC1ALDH1A1 | |
| SCHEMBL12806567 | 0.74 | ADRA2C (0.38) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL13979791 | 0.74 | ALDH1A1 (0.32) | ADRA2CKMT2AMEN1PABPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116288929-A | Preparation method of polyurethane nanofiber membrane | 浙江技立新材料股份有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | claimed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | claimed |
| EP-0571903-B1 | A method for preparing low free formaldehyde methylol-hydantoins and compositions thereof | LONZA AG (US) | 1996-08-28 | — | — | EP | claimed |
| CN-114657611-B | Alkaline copper electroplating solution and electroplating method thereof | 佛山市诺诚科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11739239-B2 | Thermally crosslinkable composition | SUNSTAR ENGINEERING INC. (JP) | 2023-08-29 | — | — | US | disclosed |
| CN-116323045-A | Silver powder, method for producing same, and conductive resin composition | 三井金属矿业株式会社 | 2023-06-23 | — | — | CN | disclosed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | disclosed |
| CN-107603357-B | Coating material for forming conductive release layer, method for producing same, conductive release film, and method for producing same | 信越聚合物株式会社 | 2020-10-16 | — | — | CN | disclosed |
| US-20200115505-A1 | POLYMERIZED IN-SITU HYBRID SOLID ION-CONDUCTIVE COMPOSITIONS | Blue Current, Inc. | 2020-04-16 | — | — | US | disclosed |
| CN-109071487-A | PROCESS FOR THE PREPARATION OF HERBICIDAL COMPOUNDS | 先正达参股股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0839339-A1 | PHOTOGRAPHIC SYSTEM | POLAROID CORPORATION (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0816341-A1 | Process for the preparation of chiral succinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997043691-A1 | PHOTOGRAPHIC SYSTEM | POLAROID CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0144990-B1 | PROCESS FOR PREPARING SILVER HALIDE EMULSION | FUJI PHOTO FILM CO., LTD. (JP) | 1990-04-25 | — | — | EP | disclosed |
| US-4665017-A | GRAIN GROWTH PROMOTOR AND INHIBITOR | FUJI PHOTO FILM CO., LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| EP-0144990-A2 | Process for preparing silver halide emulsion | FUJI PHOTO FILM CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | ADRA2C 4563/4885KMT2A 1080/4885MEN1 2213/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | ADRA2C 4579/4885KMT2A 999/4885MEN1 2164/4885 |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | ADRA2C 95/4885KMT2A 1324/4885MEN1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.